GSK plc 6-K, filed Nov 7, 2022
GSK plc (GSK)
6-K
2022-11-07
For: 2022-11-07
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on November 7, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . Form
40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 7 November 2022, London UK
GSK provides update on DREAMM-3 phase
III trial for Blenrep in relapsed/refractory multiple
myeloma
GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase
III open-label, randomised head-to-head superiority trial
of Blenrep (belantamab mafodotin) monotherapy versus
pomalidomide in combination with low dose dexamethasone (PomDex) in
patients with relapsed or refractory multiple myeloma (RRMM), did
not meet its primary endpoint of progression-free survival
(PFS).
In the DREAMM-3 trial, the primary endpoint of PFS demonstrated
a hazard
ratio (HR) of 1.03 (95% CI: 0.72 1.47). The observed
median progression-free survival was longer for belantamab
mafodotin vs PomDex (11.2 months vs 7 months). Secondary endpoints
include overall response rate (ORR), duration of response (DOR) and
overall survival (OS). The ORR was 41% for belantamab
mafodotin and 36%
for PomDex. Belantamab mafodotin demonstrated
a deeper response rate when compared with PomDex (25% VGPR or
better with belantamab
mafodotin compared
to 8% with PomDex). The
median follow-up was 11.5 months for belantamab
mafodotin and 10.8 months for PomDex; the median DOR was not
reached for belantamab
mafodotin (95%
CI: 17.9, --) vs 8.5 months (95% CI: 7.6, --) for PomDex; DOR rates
at 12 months were 76.8% and 48.4% for belantamab
mafodotin and PomDex respectively. The safety and tolerability
profile of belantamab mafodotin was consistent with the known
safety profile, and no new safety signals were identified. Overall
rates of grade 3 keratopathy are consistent with prior reported
data.
At the time of the primary analysis, the OS data had only achieved
37.5% overall maturity. The
median OS was 21.2 and 21.1 months for belantamab
mafodotin and
PomDex, respectively, with an HR of 1.14 (95% CI: 0.77,
1.68).
Blenrep was
granted accelerated approval by the US Food and Drug Administration
(FDA) as a monotherapy for treating adult
patients with RRMM who have received at least four prior therapies,
including an anti-CD38 monoclonal antibody, a proteasome inhibitor,
and an immunomodulatory agent. The accelerated approval
was based on the results of the DREAMM-2 overall response
rate, DOR
and contingent
upon a confirmed clinical benefit from a randomised phase III
clinical trial. Data from DREAMM-3 is in
the process of being shared with health authorities. Discussions
with health authorities are currently ongoing.
Additional trials within the DREAMM (DRiving Excellence in
Approaches to Multiple Myeloma) clinical trial programme will
continue. These trials are designed to demonstrate the benefit
of Blenrep in combination treatment with novel
therapies and standard-of-care treatments in earlier lines of
therapy and dosing optimisation to maintain efficacy while reducing
corneal events. Data from the DREAMM-7 and DREAMM-8 phase III
trials are anticipated in the first half of
2023.
About DREAMM-3
The DREAMM-3 phase III trial is an open-label, randomised trial
evaluating the efficacy and safety of single-agent belantamab
mafodotin compared to PomDex in patients with
RRMM. A
total of 325 participants
were randomised in a 2:1 ratio to receive either single agent
belantamab mafodotin administered as a 2.5 mg/kg dose every three
weeks (Q3W), or PomDex. Pomalidomide was administered daily on days
1 to 21 of each 28-day cycle, with dexamethasone administered once
weekly (days 1, 8, 15, and 22 of each cycle). The primary endpoint
was PFS. Secondary endpoints include safety, OS, overall response
rate, DOR and assessment of minimal residual
disease.
About DREAMM-7
DREAMM-7 is evaluating the safety and efficacy of belantamab
mafodotin in combination with bortezomib and dexamethasone versus
daratumumab in combination with bortezomib and
dexamethasone.
About DREAMM-8
DREAMM-8 is assessing the efficacy and safety of belantamab
mafodotin in combination with pomalidomide and dexamethasone
compared with that of a combination of pomalidomide, bortezomib and
dexamethasone in participants with relapsed/refractory multiple
myeloma.
About multiple myeloma
Multiple myeloma is the second most common blood
cancer in the US and is generally considered treatable, but not
curable.[1],[2] In
the US, more than 32,000 people are estimated to be diagnosed with
multiple myeloma this year and nearly 13,000 people will die from
the disease.[3] Research
into new therapies is needed as multiple myeloma commonly becomes
refractory to available treatments.[4]
About B-cell maturation antigen (BCMA)
The normal function of BCMA is to promote plasma cell survival by
transduction of signals from two known ligands, BAFF (B-cell
activating factor) and APRIL (a proliferation-inducing ligand).
This pathway has been shown to be important for myeloma cell growth
and survival. BCMA expression is limited to B cells at later stages
of development. BCMA is expressed at varying levels in myeloma
patients and BCMA membrane expression is universally detected in
myeloma cell lines.[5]
About Blenrep
Blenrep is
an antibody drug conjugate comprising a humanised BCMA monoclonal
antibody conjugated to the cytotoxic agent auristatin F via
non-cleavable linker. The drug linker technology is licensed from
Seagen Inc.; monoclonal antibody is produced using POTELLIGENT
Technology licensed from BioWa Inc. a member of the Kyowa Kirin
Group.
GSK in oncology
GSK
is focused on maximising patient survival through transformational
medicines. GSK's pipeline is focused on immuno-oncology, tumour
cell targeting therapies and synthetic lethality. Our goal is to
achieve a sustainable flow of new treatments based on a diversified
portfolio of investigational medicines utilising modalities such as
small molecules, antibodies, and antibody-drug conjugates, either
alone or in combination.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Madeleine
Breckon
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1]CA: A Cancer Journal for
Clinicians, Vol. 70, Issue 1,
Han/Feb 2020 Pages 7-30.
[2] Kazandjian
D. Multiple myeloma epidemiology and survival: A unique
malignancy. Semin
Oncol.
2016;43(6):676-681.
doi:10.1053/j.seminoncol.2016.11.004.
[3] SEER
Cancer Facts & Figures 2019. Available at:
https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed October
2021.
[4] Nooka
AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed and
refractory multiple myeloma. Blood.
2015;125(20).
[5] Lonial,
S, et al. Belantamab mafodotin for relapsed or refractory multiple
myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2
study. Lancet
Oncol. 2020;
21(2):207-21.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
07, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|